By binding to certain receptors in the bladder, Myrbetriq can help treat an overactive bladder. This prescription medication has been shown to help reduce the number of wetting accidents and minimize the number of times people have to urinate each day. It comes as an extended-release tablet that is taken once daily. Side effects may include headaches, common cold symptoms, and urinary tract infections.
Myrbetriq™ (mirabegron) is a prescription medication approved to treat an overactive bladder (also sometimes called urge incontinence). It is used to help treat the following overactive bladder symptoms:
- Frequent urination
- An urgent need to urinate
- Urine leakage that results from needing to urinate immediately.
This medication is made by Astellas Pharma Technologies, Inc., for Astellas Pharma US, Inc.
Myrbetriq works by binding to a receptor in the bladder known as the beta-3 adrenergic receptor. By binding to this receptor, Myrbetriq relaxes the bladder muscle as it is filling. This allows the bladder to fill more fully and store more urine.
Clinical studies have shown that Myrbetriq can reduce the number of times people with an overactive bladder urinate each day. The medication can also reduce the number of times people have wetting accidents.
In one of the studies, people given Myrbetriq had, on average, 1.6 fewer wetting accidents each day and had to urinate 1.9 fewer times throughout the day. In comparison, people given a placebo (a "sugar pill" that does not contain any active ingredients) had 1.2 fewer wetting accidents and urinated 1.3 fewer times a day.